The future of post-weight loss skincare starts at IMAGE with these new products
In the world of modern aesthetics, few developments have sparked as much excitement — and concern— as the widespread use of GLP-1 medications for rapid weight loss. These groundbreaking therapies have offered millions a renewed sense of health and well-being. Yet, for all their benefits, they often leave one visible drawback: their impact on the skin.
Rapid fat loss, particularly in the face, can lead to noticeable changes in skin appearance, including volume deflation, deepening wrinkles, dryness and a loss of density. Recognizing this, IMAGE Skincare has introduced a pioneering solution: VOL.U.LIFT, the first clinically formulated skincare product designed specifically to combat the four visible effects of GLP-1-induced weight loss on the skin.
Created by board-certified plastic surgeon Dr. Marc Ronert, VOL.U.LIFT isn't your run-of-the-mill anti-aging product. It represents a new category of targeted skincare.
Advertisement
IMAGE Skincare
At the heart of its innovation is the GLP-1 4D Skin Rebound Complex, a proprietary blend of active ingredients meticulously chosen to address the four primary signs of facial skin aging resulting from rapid weight loss: deflation, deep wrinkles, dehydration and density loss.
Dr. Ronert's approach reflects an intersection of medical science and aesthetic care, backed by years of experience treating patients who sought solutions for the facial aging effects that often follow significant weight reduction.
What makes VOL.U.LIFT so unique is its focus on restoring what the skin loses during accelerated fat loss. Facial deflation, a hallmark of GLP-1 therapy use, can age the appearance dramatically by hollowing the cheeks and under-eye areas. The advanced volumizing technology in VOL.U.LIFT helps to counteract this process, encouraging a more lifted, youthful contour.
After 12 weeks of consistent, twice-daily use, instrumental grading revealed a 20% increase in facial volume, underscoring the product's efficacy in restoring fullness to areas most impacted by fat depletion.
But volume is only one part of the equation. The skin's structure also suffers under the strain of rapid weight loss, often resulting in sagging and loss of elasticity. The GLP-1 4D Skin Rebound Complex targets these issues with ingredients designed to improve skin's bounce and resilience.
What's more, the results speak for themselves. Clinical testing showed a 23% increase in net elasticity and a 22% improvement in firmness after 12 weeks — measurable results that translate to tighter, more supple skin. These improvements not only address the visual signs of aging but also help the skin maintain its integrity as the face adapts to a new, leaner shape.
Deep wrinkles, another byproduct of reduced fat cushioning in the face, are also visibly diminished with VOL.U.LIFT. As facial support structures weaken and the skin thins, fine lines evolve into pronounced creases. VOL.U.LIFT is engineered to fill and smooth these lines by encouraging collagen synthesis and enhancing moisture retention. Users experienced a 20% reduction in wrinkles over a 12-week period, with noticeable improvement often beginning as early as four weeks. This means that while the transformation unfolds gradually, early signs of success are visible quickly, reinforcing the importance of consistent use.
Dehydration, though often overlooked, is a critical aspect of post-weight-loss skin care. Skin that loses volume also loses its ability to retain moisture efficiently, leading to a dull, tired complexion. VOL.U.LIFT combats this with deeply hydrating components that strengthen the skin barrier and improve water retention, leaving the skin plumper, more radiant and visibly revitalized. This comprehensive approach is what sets VOL.U.LIFT apart; rather than treating symptoms in isolation, it addresses the interconnected causes behind the accelerated aging many experience after GLP-1 usage.
Why You Can Trust IMAGE Skincare
IMAGE Skincare
What further elevates this innovation is the credibility and care behind its creation. IMAGE Skincare, founded in 2003 by aesthetician Janna Ronert, has always prioritized products that merge clean, botanical ingredients with clinical efficacy. The collaboration between Janna and Dr. Marc Ronert brings together the precision of surgical insight and the sensitivity of professional skincare.
Their shared vision has positioned IMAGE Skincare as a leader in science-driven, physician-formulated solutions that are also cruelty-free and accessible to both professionals and consumers. VOL.U.LIFT continues this legacy with a product that feels luxurious while performing like a professional-grade treatment.
The Final Verdict
IMAGE Skincare
For those navigating the often-unexpected changes to their appearance following GLP-1 weight loss, VOL.U.LIFT offers a reassuring and effective remedy. So, you can toss away your other serum and moisturizer for the time being, as this restorative treatment, designed with a deep understanding of the unique biological changes occurring beneath the surface of the skin, is one to impress.
Every application helps the face rediscover its definition, its structure and its glow. And ultimately, VOL.U.LIFT represents a major advancement in personalized skincare. It anticipates a need that is growing rapidly as more individuals turn to metabolic treatments for weight management, and it delivers on that need with unmatched precision and efficacy.
With visible improvements in volume, elasticity, firmness and wrinkle reduction (all within just a few months!) users can expect a smoother, fuller, more youthful complexion that reflects their internal transformation — with consistent use.
Backed by clinical testing and guided by medical expertise, VOL.U.LIFT proves that you don't have to choose between your health goals and your appearance. You can have both: resilient skin that rebounds, just like you.
This article was written by Victoria Giardina, New York Post Commerce Journalist & Content Strategist, who has spent countless hours researching, testing hundreds of products and comparing the latest makeup, skincare, hair and beauty items and trends to determine what's truly worth your hard-earned cash. She evaluates formulas, textures, ingredients and more, in addition to consulting medical and industry experts. Some of Victoria's latest conquests include testing the best vitamin C serums on the market, and a rinse-and-repeat review of the best shampoos of 2025. Victoria, who received a beauty industry essentials certification from the Fashion Institute of Technology, has been creating shopping guides for the New York Post since 2021 and previously held positions at Insider Reviews and CNN Underscored.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
2 hours ago
Daily oral GLP-1 pill could be just as effective as weekly shots: Drugmaker
Eli Lilly announced Phase 3 trials results for its daily, oral GLP-1 drug. 2:15 Drugmaker Eli Lilly says its oral, daily GLP-1 pill may offer similar weight loss results as weekly GLP-1 shots. Eli Lilly said Thursday that the company's orforglipron pill can offer up to an average of 27.3 pounds of weight loss, according to results from two of its Phase 3 trials that included more than 3,000 overweight or obese adults. "With orforglipron, we're working to transform obesity care by introducing a potential once-daily oral therapy that could support early intervention and long-term disease management, while offering a convenient alternative to injectable treatments," Kenneth Custer, an executive vice president and president of Lilly Cardiometabolic Health, said in a statement. "With these positive data in hand, we are now planning to submit orforglipron for regulatory review by year-end and are prepared for a global launch to address this urgent public health need."
CNBC
3 hours ago
- CNBC
Eli Lilly's obesity pill led to more than 12% weight loss in closely watched late-stage trial, paving way for approval
Eli Lilly on Thursday said the highest dose of its daily obesity pill helped patients lose more than 12% of their body weight, or roughly 27 pounds, at 72 weeks in a late-stage trial, paving way for its entrance into the market. Some doctors said the results appear to be comparable to, if not slightly lower, the level of weight loss seen with Novo Nordisk's blockbuster weekly GLP-1 injection for obesity, Wegovy. The data comes under what some Wall Street analysts were expecting for Eli Lilly's oral GLP-1, with hopes for weight loss of around 15%. Some doctors also made note of the number of patients on the highest dose of the pill who discontinued treatment due to side effects or any other reason in the trial. Still, other doctors lauded the results and the potential of the pill to reach new patients, such as those who are afraid of needles. "This is a strong and promising result for an oral agent," said Dr. Jaime Almandoz, medical director of the Weight Wellness Program at UT Southwestern Medical Center, calling the weight loss "a significant and clinically meaningful outcome." "Injectables have set a high bar, but this study reinforces the potential for an oral GLP-1 to be transformative in obesity care, particularly for patients who are hesitant to start or maintain injectable therapies," he continued. Dr. Mihail "Misha" Zilbermint, director of Endocrine Hospitalists at the Johns Hopkins Community Physicians, said he believes the pill "has the potential to be a game changer, as long as people can tolerate the side effects." The trial results are among the pharmaceutical industry's most closely watched studies of the year, and follow positive data in April from a phase three trial examining the experimental pill in diabetes patients. They bring Eli Lilly's pill, orforglipron, one step closer to becoming the first new, needle-free alternative in the booming market for weight loss and diabetes drugs called GLP-1s. Eli Lilly expects to submit the data to regulators by the end of the year, with plans to launch the pill in 2026, Ken Custer, president of Lilly Cardiometabolic Health, said in an interview. That launch could fundamentally shift the space, helping more patients access the treatments and alleviating the supply shortfalls of existing injections. The more convenient and easier-to-manufacturer pill could also help Eli Lilly solidify its dominance in the growing segment as other drugmakers, including its main rival Novo Nordisk, race to bring weight loss pills to market. Custer said there are roughly 8 million patients on injectable obesity and diabetes drugs, but likely around 170 million who could benefit from the medicines. "In order to meet that demand, we're going to need other options, including oral small molecules like orforglipron, which use different means of production and also don't need as sophisticated of a supply chain to distribute it to patients," he said. Dr. Amy Sheer, professor of medicine and program director of the Obesity Medicine Fellowship at University of Florida, said she hopes the pill will be less expensive than existing injections, which are costly largely due to the devices they come in. She said lower prices could help eliminate barriers to access for patients, potentially making insurers more willing to cover the drug. Many insurers still don't cover GLP-1s for obesity. Wegovy and other drugs have list prices of roughly $1,000 before insurance. The highest dose of Eli Lilly's pill helped more than 59% of patients lose at least 10% of their body weight and more than 39% of patients lose at least 15% of their weight, according to the trial results. Almandoz said the proportion of people who achieved "greater magnitudes" of weight loss was "very impressive for an oral agent," adding that many people "often overlook the proportion of people achieving these high weight loss categories" and typically focus closely on the average weight loss Orforglipron also helped lessen cardiovascular risk factors. But data on how well some patients tolerated the pill in the trial came under some analysts' estimates. About 10.3% of patients who took the highest dose of the pill — 36 milligrams — discontinued treatment due to side effects, compared with around 2.6% of those who took placebo. Those side effects were mainly gastrointestinal, such as nausea and vomiting, and mild to moderate in severity. An estimated 24% of those who took the highest dose experienced vomiting, while 33.7% and 23.1% had nausea and diarrhea, respectively. Ahead of the data, BMO Capital Markets analyst Evan Seigerman said he expected less than 10% of patients on the highest dose of the pill to discontinue treatment due to side effects and lower rates of vomiting, nausea and diarrhea. More patients stopped taking the pill due to side effects compared with existing GLP-1s on the market, said Dr. Caroline Apovian, co-director of the Center for Weight Management and Wellness at Brigham and Women's Hospital. The discontinuation rates due to side effects in late-stage trials on Wegovy and Eli Lilly's weekly obesity injection Zepbound are around 7% or less. She noted that almost a quarter of patients on the highest dose of the pill discontinued treatment for any reason, cautioning that the enthusiasm for orforglipron should be tempered "because we get all this excitement, and then the pill comes out, and then nobody can take it." It's unclear why, apart from side effects, those patients discontinued the pill. But University of Florida's Sheer said she doesn't believe the discontinuation rates or side effects will be a deciding factor for physicians when prescribing the pill. She believes an oral option could actually make more physicians more comfortable prescribing a GLP-1 to patients. Some physicians are currently hesitant to prescribe injections because they "may not know how to tell patients how to use them," Sheer added. Almandoz said prescribing decisions are going to depend on the patient's specific needs and preferences, as well as access and affordability. An injectable GLP-1 may be the preferred option for patients whose priority is a greater level of weight loss or those who have significant cardiometabolic complications, or health issues that arise from cardiovascular diseases and metabolic disorders. But an oral GLP-1 could be the best fit for those who "prioritize simplicity or convenience or have these logistical challenges with injections," he said. The detailed results from the trial will be presented in September at a European medical meeting and published in a peer-reviewed journal. More phase three trial results on the pill will be shared later this year, including from a study on adults who have obesity or are overweight and have Type 2 diabetes. Wegovy, Eli Lilly's pill, orforglipron and Novo Nordisk's diabetes pill Rybelsus all work by targeting a gut hormone called GLP-1 to promote weight loss and regulate blood sugar. But unlike those other medications, Eli Lilly's pill is not a peptide medication. That means it is absorbed more easily in the body and doesn't require dietary restrictions like Rybelsus does. Eli Lilly is currently about three years ahead of other drugmakers developing pills, including Pfizer, AstraZeneca, Roche, Structure Therapeutics and Viking Therapeutics, Guggenheim analyst Seamus Fernandez previously CNBC. Some analysts expect the market for GLP-1s to be worth more than $150 billion annually by the early 2030s. Oral GLP-1s could grow to be worth $50 billion of that total, Fernandez said.
Time Magazine
3 hours ago
- Time Magazine
Eli Lilly Says Its New Weight-Loss Pill Is Highly Effective
In eagerly awaited results from a new study, the pharmaceutical company Eli Lilly reports that a pill its scientists developed causes people who are overweight or obese, but not diabetic, to lose significant amounts of weight. The drug, called orforglipron, differs from Lilly's injectable drug, tirzepatide (which is approved as Mounjaro to treat diabetes and as Zepbound to treat obesity and some forms of obstructive sleep apnea). While tirzepatide targets two hormones, GLP-1 and GIP, orforglipron just targets GLP-1. Lilly and other companies that make similar medicines have been racing to create oral weight-loss drugs, since weekly injections are not always appealing to patients. The trial included more than 3,100 overweight or obese adults who had an obesity-related medical problem but not diabetes. Those taking the pill daily for almost a year and a half lost 12% of their body weight on average, or 27 pounds. People taking a placebo lost just over two pounds. The findings have not yet been published in a peer-reviewed journal but will be presented in September at the annual meeting of the European Association for the Study of Diabetes. Based on the results, Lilly says it plans to file for approval of orforglipron from the U.S. Food and Drug Administration to treat obesity by the end of the year. If approved, Lilly says, it will be able to provide the pills by next year. The company is waiting for final results from a similar study of weight loss in people with diabetes; early results released in April indicate that the drug helped people with diabetes lower their blood sugar. 'The results we got were as good as we can possibly achieve with an oral small molecule GLP-1," says Dr. Dan Skovronsky, Lilly's chief scientific officer. 'The safety, tolerability, and efficacy were all in line with what we achieved with the injectable drug, yet now delivered in an easy-to-use, once-a-day pill.' Read More: The Health Risks and Benefits of Weight-Loss Drugs Among people in the study who took the drug, risk factors for heart disease such as LDL cholesterol, triglycerides, blood pressure, and a marker of inflammation also dropped, Skovronsky notes. That supports earlier data finding that GLP-1 drugs can lower the risk of heart disease as well. As with the injectable form, people taking the pills had to gradually increase their dose before reaching the maximum dose, mainly to minimize the side effects of gastrointestinal distress. In the study, people started out at 6 mg, then increased to 12 mg four weeks later, then to the maintenance dose of 36 mg four weeks after that. Orforglipron's side effect profile was similar to that of the injectable drugs, which is reassuring, says Skovronsky. 'There were two things I worried about,' he says. 'One, when you take something orally, you are exposing the stomach and intestines to a higher concentration of the drug. If that's where the side effects are caused, then [the oral] form could make them worse. But it wasn't the case at all.' It also wasn't clear what would happen if people in the study missed doses, since it's sometimes challenging to take a pill every day. Because the dose is carefully titrated up, Skovronsky said it wasn't known if people who missed pills for a few days would lose the tolerance they had built up to the side effects and have to restart their dosing schedule. 'What we found was that the side effects were similar to the injections, even though people missed the dose every once in a while,' he says. Read More: Is Ozempic the New Anti-Inflammatory Wonder Drug? Novo Nordisk, a competitor that makes Ozempic for treating diabetes and Wegovy for weight management, also has an oral form of its active ingredient, semaglutide, that is already approved to treat diabetes. The company has applied for approval to treat obesity in people without diabetes and expects a decision by the end of the year. If orforglipron is approved, it could increase access to GLP-1 medications in the U.S. and around the world. The oral drug is cheaper than the injectable, since it does not require a sterile injectable pen. Some people are also reluctant to inject themselves weekly, so taking the medication by mouth would be a welcome option. As more doctors and patients figure out the best way to use GLP-1 drugs to manage weight, a pill could either kickstart weight loss or become part of a long-term maintenance program for people who have hit their weight-loss goal. 'This can enable us to go earlier in the disease course, because people sometimes hold off on the injections until the disease—in this case, obesity—is more severe,' says Skovronsky. 'We want to treat obesity at its earliest stages, and this provides a good opportunity to do that.' Skovronsky says Lilly is also studying weight-maintenance approaches with orforglipron.
